A-Alpha Bio retools yeast mating for high throughput drug discovery

A-Alpha’s screening tech exploits yeast mating to optimize biologics, modulate protein-protein interactions

A-Alpha Bio is co-opting yeast mating to scale up screening of candidates that create or block protein-protein interactions. The University of Washington spinout is partnering with drug developers to find biologics with defined specificity profiles, small molecule “molecular glues” for targeted protein degradation and agents that disrupt protein complexes.

“Protein-protein interactions govern just about every process in biology,” said A-Alpha Bio Inc. CEO David Younger. “If

Read the full 653 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE